Frontlight ResearchEarly access
Not yet taking people in NetherlandsPhase 3
Tests hospital-made CAR T-cells against standard care for returned multiple myeloma
Compares hospital-made CAR T-cells with standard treatment in adults with relapsed myeloma.
Key facts
- Who runs it
- Universitair Medisch Centrum Groningen
- Where
- Groningen, NetherlandsSee the site
- Trial code
- Registry title
- A study investigating the safety and efficacy of academically-produced CAR T cells compared with standard treatment for patients with multiple myeloma whose disease has returned or not responded to previous treatments.
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 126 people, planned
- Started
- 1 Aug 2026
- Expected to end
- 1 Aug 2030
- Type of study
- Interventional
- Record updated
- 29 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple myeloma that came back or stopped responding after 2 to 4 earlier treatments. It compares ARI0002h CAR T-cells with standard treatment.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Multiple myeloma that no longer responds to the last treatment, with disease that can be measured at screening. ECOG/WHO performance status of 0-2.
- Earlier treatment
- Must have had 2 to 4 earlier lines of myeloma treatment, including an IMiD, a PI and an anti-CD38 antibody. Must not have had BCMA-targeted therapy, T-cell engager therapy, CAR T-cell therapy or other genetically modified T-cell therapy.
Main reasons for not taking part
- Myeloma in the brain, spinal fluid or heart
- Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome or amyloidosis
- Uncontrolled infection or infection needing IV antimicrobials
- Pregnant or breastfeeding women, or people not willing to use highly effective birth control
- Life expectancy under 12 weeks, or taking part in another clinical trial
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Documented historical diagnosis of Multiple Myeloma
- Received 2 to 4 prior lines of antimyeloma therapy, including an IMiD, a PI and an anti-CD38 mAb
- Refractory to the last line of treatment by IMWG criteria
- Measurable disease at screening per IMWG criteria
- Candidates to receive at least 1 of the 5 SoC regimens (PVd, PCd, EPd, DKd or Kd)
- Aged 18 years or older
- Capable of giving informed consent
- ECOG/WHO performance status of 0-2
- Adequate hematological, renal, hepatic, pulmonary, and cardiac function
Who cannot take part
- Received one of the following prior therapies: BCMA-targeted therapy, T-cell engager therapy, CAR T-cell therapy, or other genetically modified T-cell therapy
- Active or prior history of central nervous system (CNS) or meningeal involvement of MM
- Cardiac atrial or cardiac ventricular MM involvement
- History of or active plasma cell leukemia, Waldenstrom’s macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes (POEMS) syndrome, or amyloidosis
- Presence or suspicion of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management
- Females who are pregnant or breastfeeding
- Participants who are not willing to practice highly effective birth control
- Life expectancy < 12 weeks
- Current participation in another clinical trial
Where in Netherlands
- Universitair Medisch Centrum GroningenGroningen, NetherlandsNot yet recruiting
About the trial
What the trial wants to find out
To compare progression free survival (PFS) of patients randomized to PoC ARI0002h CAR T-cells versus current SoC in patients previously treated with 2-4 lines of therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- HO183 CAR T: A phase III randomized trial comparing academically produced BCMA-directed CAR T-cells (ARI0002h) with standard of care regimen in patients with relapsed/refractory multiple myeloma
- Plain-language title
- Tests hospital-made CAR T-cells against standard care for returned multiple myelomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 29 April 2026